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of Gene Regions Associated with Crohn Disease
Heather Elding,1 Winston Lau,1 Dallas M. Swallow,1 and Nikolas Maniatis1,*
The risk of Crohn disease (CD) has a large genetic component. A recent meta-analysis of 6 genome-wide association studies reported
71 chromosomal intervals but does not account for all of the known genetic contribution. Here, we refine localization of the previously
reported intervals and also identify additional CD susceptibility genes using a mapping approach that localizes causal variants based on
genetic maps in linkage disequilibrium units (LDU maps). Using 2 of the 6 cohorts, 66 of the 71 previously reported loci are confirmed
and more precise location estimates for these intervals are given. We identify 78 additional gene regions that pass genome-wide sig-
nificance, providing strong evidence for 144 genes. Additionally, 56 nominally significant signals, but with more stringent and precise
colocalization, are identified. In total, we provide evidence for 200 gene regions confirming that CD is truly multifactorial and complex
in nature. Many identified genes have functions that are compatible with involvement in immune/inflammatory processes and seem to
have a large effect in individuals with extra ileal as well as ileal inflammation. The precise locations and the evidence that some genes
reflect phenotypic subgroups will help identify functional variants and will lead to greater insight of CD etiology.Crohn Disease (CD) is, like ulcerative colitis (UC), a major
subtype of Inflammatory Bowel Disease (IBD [MIM
266600]). Although CD differs from UC in several respects
(e.g., clinical manifestations, cytokine profile), they both
involve chronic intestinal inflammation but with variable
and somewhat overlapping manifestations. CD principally
involves the ileum, but there is variation in disease pheno-
type. There are inflammatory, stricturing, or penetrating
types that may affect different sites in the gastrointestinal
tract (GI) and also differences in the age of onset. This
variability results from the interaction of environmental
factors, including gut microbiota and the immune and
inflammatory mechanisms of the genetically susceptible
host. CD is a polygenic disorder with some high-pene-
trance genes and an estimated individual sibling recur-
rence risk ratio (ls) ranging from 15 to 30.1 Because of
this high ls, CD is one of themost widely studied common
multifactorial diseases. The genetic contribution was first
explored by linkage analysis using families, which led to
the important identification of the role of NOD2 on
chromosome 16q (MIM 605956). Further progress was
subsequently made through genome-wide association
studies (GWASs).2–11 A recent meta-analysis explored 6
GWASs and identified a total of 71 signals of association
with CD using more than 6,000 cases and 15,000
controls.5 The authors estimated that these loci explain
less than one quarter5 of the reported heritability in
liability. A GWAS utilizes hundreds of thousands of
SNP markers across the genome. There is a lack of power
to detect genome-wide association partly because of (1)
the highly stringent significance thresholds required as a
result of multiple testing, and (2) the unrealistic assump-
tion that by testing each SNP one at time, one of the
markers in the genotyping platform used will either be
the causal or in almost complete linkage disequilibrium1Research Department of Genetics Evolution & Environment, University Coll
*Correspondence: n.maniatis@ucl.ac.uk
http://dx.doi.org/10.1016/j.ajhg.2012.11.004. 2013 by The American Societ
The Americ(LD) with the causal variant. An additional problem is
that in order to achieve sufficient power, studies are often
combined with the aim of increasing sample size. As a
result, data sets often include cases with variable disease
onset, variable phenotype definition, and sample collec-
tion in different geographic regions. Taken together, this
not only means that rare variants of large effect are likely
to be missed but that common variants with small effect
or that apply only to a particular subgroup could also be
missed.
Our recent study of the chromosome 16q linkage region
using two of these GWASs illustrated how a multimarker
approach based on high-resolution LD maps can provide
additional study power. We were also able to explain
heterogeneity in a genomic region first identified by
linkage analysis.12 By using UK data provided by the
Wellcome Trust Case Control Consortium (WTCCC), we
identified, on this chromosome arm, with high statistical
confidence, several new gene regions that are involved
in inflammation and immune dysregulation. These dis-
tinct signals were replicated with high precision of loca-
tion using independent North American data provided
by the National Institute of Diabetes and Digestive and
Kidney Diseases IBD Genetics Consortium (NIDDK). The
study highlighted the importance of genetic heterogeneity
(i.e., the involvement of different risk genes in different
individuals) within the extensively studied NOD2 gene
region and demonstrated the independent involvement
of the nearby CYLD (MIM 605018).12 We also illustrated
the importance of accurate and detailed phenotype defini-
tion in revealing gene association. By examining the
group of NIDDK cases that had involvement of nonileal
intestinal regions, as well as the ileum, we were able to
replicate association with CDH1 (encoding E-cadherin
[MIM 192090]), which is located coincident with aege London, Gower Street, London WC1E 6BT, UK
y of Human Genetics. All rights reserved.
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Figure 1. Localization within the IL1RL1/IL18RAP Region
The LD map of the region is shown by plotting LDU (y axis)
against kb (x axis). The red vertical arrows are the estimated loca-
tions S^ for the WTCCC and NIDDK data sets. The WTCCC S^ is
within an intron and between a miRNA (mIR4772) and coding
rare variant associated with CD within IL18RAP (NM_003853.2)
c.1579G>T (p.Val527Leu).previously described linkage peak in cases without NOD2
mutations.
The purpose of this study is to analyze the whole
genome using a gene-mapping approach based on LDU
maps in order to identify additional genes for CD and
provide the basis for new etiological insights into the
disease. In order to accomplish this aim, we used 2 GWA
data sets. From the UK WTCCC GWAS data2 based on
the Affymetrix 500K Array, we analyzed a total of 1,698
cases of CD and 2,948 controls. The CD cases consisted
of individuals with any subtype of CD. The GWAS replica-
tion data consisted of 813 North American CD cases and
947 ethnically matched controls, and all cases exhibit
inflammation of the ileum. These GWAS data are available
from the NIDDK IBDGC with the genotype data derived
from the Illumina HumanHap300 Array. This array con-
sists of a much lower SNP resolution and a set of SNPs
that only partially overlap with the WTCCC 500K Affyme-
trix Array. Although a smaller data set, the NIDDK data
contains a richer phenotypic description of cases and
includes the various additional locations of intestinal
inflammation for each individual. Further details about
the GWAS data sets are available in other reports.2,11
The mapping approach in this study uses genetic
locations derived from a high-resolution LD map with
distances in LD units (LDU).13 High-density LDU maps
were constructed using data from the HapMap Phase II
Project. They can be visualized by plotting marker location
in LDU against the marker distances in kb. Plotting these
LDU maps reveals the nonlinear relationship between
physical distance and the underlying LD together with
the ‘‘block-step’’ structure of the region in question (see
Figure 1). ‘‘Blocks’’ of LD represent areas of low haplotype
diversity whereas ‘‘steps’’ define LD breakdown mainly
caused by recombination because crossover profiles agree
with LD patterns.14
The construction of the LDU maps is based on the
Male´cot Model, which describes the decline of pairwise
SNP associations as a function of physical distance in
kilobases (kb).13 For the association mapping analyses, all
the SNPs in the WTCCC and NIDDK data sets were
assigned an LDU location from the HapMap LDU maps.
We then divided each chromosome arm into nonoverlap-
ping analytical windows, which were constrained to 10
LDU and a minimum of 60 SNPs. The windows were iden-
tical for both data sets. For each window along the whole
genome, a composite-likelihood test15 was used, in which
all the SNPs within a window are simultaneously tested.
Therefore, the method avoids the need for imputation.
Because each window is a test, then the total number of
tests performed is substantially lower than single SNP
analysis. This has important implications in multiple
testing. Each test is also based on the same Male´cot model
used to construct the LDU maps, although in this case, we
model the decline of affection-status-by-SNP association as
a function of genetic distance in LDU. The model uses the
locations from the LDU map in order to estimate the most108 The American Journal of Human Genetics 92, 107–113, January 1likely location (S^) of the causal agent. The method returns
a p value for association of the window together with an
estimated S^ for each window. In windows where S^mapped
to the end of a window-boundary, that window was
extended in that direction to capture information on the
far side to improve the accuracy of location. The con-
struction of the LDU maps using the HapMap Phase II
data has been described in detail elsewhere16 and the asso-
ciation mapping methodology presented here using the
LDU maps is given by Maniatis et al.15 This method has
been shown to increase power and localization over kb
maps.12,15
Our recent work12 showed that stratifying the analysis
according to the occurrence of extraileal intestinal involve-
ment, as opposed to ileal inflammation alone (a subdivi-
sion that appears to accompany genetic stratification17),
further increases the power of detecting association. We
stratified the NIDDK data based on detailed information
regarding the location of individuals’ intestinal inflam-
mation. For all the analytical windows that showed
nominal statistical evidence of association using the
WTCCC data, we analyzed the same windows using the
entire NIDDK data and also using a subset of the NIDDK
data containing CD cases that reported extraileal in addi-
tion to ileal inflammation. Unlike the controls, the vast
majority of cases in this subdivision were non-Jewish. We
therefore analyzed only non-Jewish cases with extraileal
inflammation and non-Jewish controls. This subdivision
reduced the sample size from 813 to 277 CD cases and
from 947 to 515 controls.
In an initial analysis, we looked for signals within the
previously published intervals from the recent meta-
analysis5 and present p values for the relevant data sets.
Because the majority of these intervals were more than
200 kb in length (defined around the most significant SNP
using LD information5), it was difficult to meta-analyze0, 2013
Table 1. Examples Taken from the Previously Reported Intervals, Showing the Whole-Genome Association Statistics and Closest Gene to
the Estimated Location of the Causal Agent S^
Chr
Reported LD
Interval (Mb)
Interval
Span (Mb) WTCCC S^ WTCCC p Value NIDDK S^ NIDDK p Value
Gene (WTCCC/NIDDK
If different)
1p31.3 67.36 – 67.77 0.41 67,684.8 2.1 3 1011 67,707.3 3.0 3 1010 IL23Ra
2q12.1 102.80 – 103.30 0.50 103,059.8 1.8 3 1008 102,951.7 1.7 3 1005 IL18RAPa/IL1RL1a
2q37.1 234.15 – 234.57 0.42 234,144.8 5.6 3 1025 234,171.9 2.2 3 1009 ATG16L1a
5q31.1 129.38 – 132.02 2.64 131,748.2 2.7 3 1022 131,631.4 8.9 3 1007 C5orf56a/SLC22A4a
16q12.1 50.46 – 50.85 0.39 50,803.2 2.6 3 1015 50,803.2 1.1 3 1009 NOD2a
50,846.3 1.6 3 1013 50,846.5 4.1 3 1004 CYLD
aAt least one of the estimated locations S^ is located within the identified gene. All locations in kb are in NCBI 37. Full details on the entire list of 71 LD intervals are
given in Table S1.the results obtained using this mapping procedure. We
therefore present the p values obtained from WTCCC
and NIDDK separately. For the additional genes we identi-
fied, we present a meta-analysis p value for each analytical
window that shows (1) evidence of nominal statistical
significance for each data sample and (2) that the S^ esti-
mates for both samples are within 150 kb of one another.
These two criteria were used in order to reduce the possi-
bility of heterogeneity and thus facilitate the meta-analysis
of shared locations. In order to account for multiple
testing, we used a Bonferroni p value threshold of 1 3
105, which corresponds to the 4,993 tests, to the final
meta p value. This number of tests included the total
number of analytical windows across the genome (4,399
windows with identical boundaries for both data sets)
plus the additional analyses performed for the NIDDK
data using the extraileal subgroup.
In order to capture replications of slightly lower signifi-
cance but with more precisely agreeing S^ values, we used
a second threshold in which the S^ for both data sets had
to lie within 80 kb of each other to be considered a replica-
tion and with a meta p value within the range of 1 3 103
and 1 3 105.
For nominally significant windows of each data set, the
closest gene of the estimated location S^ was retrieved
and then listed in the tables. Using BioMart, the Gene
Ontology (GO) annotations attributed to each gene were
retrieved and are listed. Using the Cytoscape plugin
BiNGO,18 we also checked for overrepresentation of GO
terms from the GO Slim GOA database using a hypergeo-
metric test.
Our first goal was to determine whether the LDU
mapping method could detect the 71 intervals previously
identified from the most recent large meta-analysis of six
independent data sets. Table 1 shows some examples and
Table S1 presents the statistical evidence and location
estimates, for significant signals within each of these 71
intervals.5 Our analyses identified a total 66 out of the 71
intervals (loci) in one or both of these data sets using an
uncorrected significance threshold of p < 0.05. Only five
intervals showed no evidence of association for eitherThe AmericWTCCC or NIDDK using the Male´cot model. Notably,
the first published results by the WTCCC2 reported just
nine loci, but Table S1 (available online) shows 28 signals
for the WTCCC alone that passed our genome-wide signif-
icance threshold (13105). Themajority of the66 intervals
(88%)were identifiedwith the largerWTCCCdata with the
remaining eight intervals (12%) showingnominal evidence
of association for the smaller NIDDK data set alone. Inter-
estingly, these eight include regions (e.g., 10q22, 16p11)
that have previously been implicated for pediatric IBD
cases7 (Table S1). This is consistent with the fact that the
NIDDK data set probably includes a larger number of indi-
viduals with early onset CD (~37%) than WTCCC, where
this information is not recorded. It is worth noting that
one of the six contributory data sets to the most recent
meta-analysis included entirely pediatric IBD cases.5
Unlike the recent meta-analysis, where a particular gene
or genes within these intervals was identified through a
series of in silico analyses, we present the genes closest to
the location estimates we have obtained using this method
(Table 1; Table S1). In several instances, these agree with
the previously identified genes (e.g., STAT3 [MIM 102582],
IL23R [MIM 607562]; Table S1), but in other instances
there are differences. For several regions, we obtain two
different estimates of localization (S^) for WTCCC and
NIDDK, both within the same interval. Heterogeneity in
some regions is expected and location estimates can help
identify this. For example, for the interleukin-rich interval
(2q12.1), the WTCCC data set yielded an estimate within
IL18RAP (MIM 604509) but for NIDDK the S^ is within
IL1RL1 (MIM 601203; Table 1). Both genes have been
previously suggested as candidates within the 2q12.1
interval,5 but an independent fine mapping study has
shown strong association to the IL18RAP rs917997 SNP
for both CD and UC,19 which is approximately 10 kb
away from WTCCC S^ (Table 1; Figure 1). A recent study20
using deep sequencing identified a rare coding variant
of possible functional significance within IL18RAP
(NM_003853.2:c.1579G>T [p.Val527Leu]), which is only
8 kb away from theWTCCC location, though it is probable
that other functional variants are also involved. As far asan Journal of Human Genetics 92, 107–113, January 10, 2013 109
Table 2. Whole-Genome Association Statistics and the Closest
Gene to the Estimated Location of the Causal Agent for the 78
Gene-Regions that Passed Our Genome-Wide Significance
Threshold 1 3 105 with S^ Locations of 150 kb or Less between the
Two Data Sets
Chr Gene region (WTCCC/NIDDK if different)
1 NFIAb, PGM1a/EFCAB7a,b, RORCa/THEM4, KCNK1a,b,
LGALS8a, ACTN2a/HEATR1
2 LOC400940, FAM49A, DNAJC27-AS1a/ADCY3a,
DCTN1a/RTKNa,b, intergenic (2q14.1), STK39a,
ZNF804Aa, ERBB4a
3 STAC/ARPP21, ITGA9a, EPHA6b, COL8A1
4 TECa/SLAIN2, LNX1/RPL21P44b, PDGFRAb,
COL25A1a,b, SNX25a
5 MCCa,b, MEGF10/PRRC1b
6 GPLD1a, GABBR1a, EYSa, FNDC1a, Tb,
7 MACC1/TMEM196, NPYb, INHBA-AS1/GLI3, SEMA3Ca,
TSPAN12/KCND2a, intergenicb (7q31.33), PODXLb
8 MTUS1a, LOC100507632, STMN2b, intergenic (8q21.13),
DCAF13/FZD6b, intergenicb (8q23.3)
9 DOCK8a,b
10 GPR158a,b, FAM13Ca, ARID5B/C10orf107, PLAUb,
KCNMA1a, XPNPEP1, NRAPa
11 OR52N4/OR52N2b, BDNF, OR9G4, KIRREL3a
12 CCDC91b, TMEM117a,b, C12orf74b, ANO4a
13 MIR4703
14 PNN/GEMIN2a,b, NRXN3a,b
15 OTUD7Aa, PGBD4/CHRM5a
16 RBFOX1b, RBFOX1a, BRD7, HSD11B2b, IRF8
17 GRB2a/MIR3678
18 GATA6, RIT2a,b, IER3IP1b
20 HAO1a,b, LOC339568, CD40/SLC12A5a,b
22 CSF2RBa/LOC1005006241
X FMR1NB
bold denotes that the signal is replicated using the data stratified according to
non-Jewish ileal and extraileal inflammation.
aAt least one of the estimated locations S^ is located within the identified gene.
bThe signal is significant in the pooled NIDDK data as well as the stratified non-
Jewish ileal and extraileal data set. All locations in kb are in NCBI 37. Full details
(p values and estimates of S^) are given in Table S2.
Figure 2. Localization within the ERBB4 Region
The LD map of the region is shown by plotting LDU (y axis)
against kb (x axis). The red vertical arrows are the estimated loca-
tions S^ for the WTCCC and NIDDK data sets.the second gene is concerned, the importance of IL1RL1
to inflammatory processes has also been documented21
for a variety of human pathologies including celiac
disease.22 The LDUmap clearly shows that there are several
recombination hot spots between IL18RAP and IL1RL1
(Figure 1) making it likely that these two signals are
independent and that there is genetic heterogeneity
within these previously identified intervals. This result is
similar to that previously noted in the case of NOD2 and
CYLD12 (Table 1).
As well as our 66 localization estimates, we identified
134 additional signals, of which 78 passed our genome-
wide significance threshold (1 3 105; Table 2; Table S2).110 The American Journal of Human Genetics 92, 107–113, January 1Of these 78 signals, 64 were replicated using the complete
NIDDK data set, of which half (32) were also replicated in
the smaller subset of the data (ileal and extraileal). How-
ever, notably, in half of these (16) the association showed
higher significance in the smaller subset despite the
substantial decrease in the number of cases and controls
(see entries in boldmarked with b in Table 2). Furthermore,
the remaining 14 (22%) of the WTCCC signals were only
replicated using this subset of the NIDDK data.
For the majority (74%) of the 78 signals, the location
estimates from both data sets point to the same gene,
with approximately half of the signals being intragenic
and half intergenic locations (gene with ‘‘a’’ indicates that
at least one of the signals is within the gene; Table 2). In
all signals, including the ~50% that reside outside of genes,
the closest gene is considered as a candidate. It should
however be noted that in some instances, functional
variation in cis-elements that regulate genes far away from
the location determined here may be involved.23
Several of the additional genes we identified have been
reported to be involved in inflammatory and/or immune
dysregulation conditions (e.g., DOCK8 [MIM 611432],
ITGA9 [MIM 603963]). In other instances, the genes have
been previously implicated in colonic inflammation or
epithelial cell morphology based on functional studies.
By way of illustration, Figure 2 presents an example of
the estimated locations (S^) for the genomic region that
harbors ERBB4 ([MIM 600543], 2q34 window). For both
data sets, this window was significantly associated with
CD with a meta p value of 3 3 106 (Table 2). Figure 2
also shows the LDU map starting from the 30 region and
spanning halfway along the gene, which stretches across
more than 1 megabase (Mb). The map shows numerous
short LD blocks across the region. However, despite the
large LD breakdown in the area, both estimates of S^ are
close to each other and within the same intron. Interest-
ingly, ERBB4 (which encodes Receptor protein-tyrosine0, 2013
Table 3. List of Genes for the 56 Signals with p Values 103105
and with S^ Locations of 80 kb or Less between the Two Data Sets
Chr Gene region (WTCCC/NIDDK if different)
1 LOC400752, DAB1a, GADD45A, intergenic (1p31.1),
intergenicb (1q31.3), RENa, DNAH14a, H3F3Ab
2 ETAA1b, IL1R2a, LRP2a, NYAP2
3 CACNA2D3, ROBO2a, BTLAa, AGTR1a
4 HSP90AB2b, intergenic (4q13.2), PRDM5a
5 CDH12, intergenic (5q21.1), FAM71B/ITKa,b
6 SOX4, BEND3a, MARCKS, STLb, IFNGR1,
intergenic (6q25.3), SNX9a,b
7 MACC1, NPSR1a, IQUBb, KELa
8 SLAa
9 C9orf85/C9orf57, GNA14a,b, intergenic (9q33.1)
10 FASb
11 MOB2a, MICALCLa
12 CAND1, KITLGb, LOC100128554b
13 GPR12, NBEAa, intergenic (13q31.3),
intergenic (13q31.3)
14 intergenicb (14q31.1)
15 ATP8B4a
16 CDH8a, CNTNAP4, WWOXa,b
20 MACROD2a
21 DSCAMa
22 ISXb
X intergenic (Xq23)
bold denotes that the signal is replicated using the data stratified according to
non-Jewish ileal and extraileal inflammation.
aAt least one of the estimated locations S^ is located within the identified gene.
bThe signal is significant in the Pooled NIDDK data as well as the stratified non-
Jewish ileal and extraileal data set. All locations in kb are in NCBI 37. Full details
(p values and estimates of S^) are given in Table S3.kinase erbB-4) is expressed at high levels in the inflamed
colonic mucosa of CD cases.24 Using adult mouse colon,
it was also shown that ERBB4 is an important regulator
in the epithelial response to inflammation and injury.24
ERBB4 expression has been linked to a number of cellular
processes such as cell survival, proliferation, and tumori-
genesis in different tissues.25,26 A recent study suggested
that this elevated ERBB4 expression could lead to colitis-
associated development of colorectal tumors.27 ERBB4
has also been implicated, together with E-cadherin
(encoded by CDH1 on 16q22.1, previously identified as
a risk gene for CD12 and ulcerative colitis28), in the
suppression of anoikis29 (programmed cell death as a result
of cell detachment from the extracellular matrix), suggest-
ing that there may be interaction between these two genes.
Despite the fact that ERBB4 is a very large gene (>1 Mb),
the estimated locations of the causal agent for both data
sets (WTCCC and NIDDK) are very close and within the
same intron, making it an excellent target for follow-up
fine mapping studies and resequencing.The AmericTable 3 shows the list of 56 of the 134 additional signals
that showed association with CD with p values that
ranged between 1 3 103 and 1 3 105. These p values
were below the Bonferroni threshold, but the windows
were selected on more stringent criteria for colocalization
(i.e., estimates of localization in the two data sets were
not more than 80 kb apart from each other). Detailed
information (p values, location estimates) for the all the
genes listed in Table 3 are given in the Table S3. As in
Table 2, most of the signals in Table 3 give estimates of S^
that point to the same gene. Several of these genes are
also very interesting. For example, the window harboring
BTLA (MIM 607925) gave location estimates that are just
2 kb apart. A study using a mouse model of colitis has
shown functional evidence of BTLA involvement in
colitis.30
In summary, using a powerful multimarker association
mapping approach based on LDU maps, we confirm 66
of the 71 previously reported loci from meta-analysis and
134 additional gene regions that are associated with Crohn
disease, providing evidence for 200 gene regions that
include CD susceptibility loci. We provide more precise
location estimates for the 66 previously published inter-
vals, as well as locations for the 134 additional signals.
This is a major step forward in identifying the relevant
genes and functional variants and thus elucidating the
genetics of CD etiology. The very large numbers of genes
listed in Tables 2 and 3 confirm that CD is truly polygenic
and complex in nature. Many genes show functions
that are compatible with involvement in immune and/or
inflammatory processes as well as integrity of the intestinal
epithelium and differentiation. The groups of genes
were enriched for GO terms such as signal transducer
activity, receptor activity, and binding. These functions
are important in inflammatory processes (see Supple-
mental Information; Tables S4 and S5).
Gene mapping by linkage has a long history, but associ-
ation mapping was in its infancy when high-throughput
SNP genotyping was developed. There is currently some
skepticism regarding the success of genome-wide associa-
tion mapping, but here we demonstrate its great potential
in dissecting the genetics of common disease—at least for
Crohn, for which relatively highly penetrant genes are
known to exist (as indicated by high lS estimates). We
also demonstrate that the use of smaller data sets and
detailed phenotypic information can detect a great pro-
portion of the genes involved, as well as genetic heteroge-
neity. Here we get a glimpse of the way in which different
genes are likely to be involved in different but overlapp-
ing pathways. Many of the replicated signals were more
significant using a subset of the North American data
(NIDDK), which contained individuals with ileal CD who
had involvement of at least one extraileal intestinal
location. Despite the substantial decrease in sample size,
analysis of this subphenotype using our mapping method
yielded much higher significance than the analysis of
the full data. This result shows that accurate and detailedan Journal of Human Genetics 92, 107–113, January 10, 2013 111
phenotype information is extremely important in genetic
studies especially when assessing a trait that shows clinical
variation.
The majority of the 200 signals unambiguously identify
single genes. Their confirmation in independent cohorts
makes it likely that most have an effect (in many instances
small, though sometimes large) on the risk of CD. The
genomic locations we provide are estimates of the posi-
tions of the variants of functional significance assuming
a monophylogenetic origin (i.e., no substantial allelic
heterogeneity). We have previously shown the greater
power of LDU compared to physical maps in detecting
association and refining location using the same multi-
marker methodology.31 The close distance between the
location estimates in the two different cohorts (10 kb or
less in 30% of the additional signals) suggests that
these allelic variants will often be the same, but in some
instances there are clear indications of independent allelic
variants. In either case, the localization offers much greater
precision than other methods for future in depth analysis
using bioinformatics and resequencing.
The identified genes will facilitate more powerful exper-
imental research designs including a range of functional
studies and analytical pathway analyses for CD. Given
the high-resolution estimates, the results presented here
will allow more targeted, intelligently designed resequenc-
ing studies, where carefully characterized, homogeneous
subgroups of cases can be more thoroughly investigated.
Such research strategies should move us closer to more
effective, personalized medical treatment for individuals
with Crohn disease.Supplemental Data
Supplemental Data includes five tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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